New York, Jan 26, 2026, 2:04 PM EST — Regular session
- Shares of Intuitive Surgical climbed roughly 1% following FDA clearance of da Vinci 5 for select cardiac procedures
- This step pushes da Vinci 5 back into a specialty it had previously pulled away from, targeting a limited U.S. rollout through 2026
- Investors are balancing the fresh guidance against last week’s warning of slower procedure growth
Intuitive Surgical shares climbed roughly 1% Monday following U.S. regulatory clearance of its newest da Vinci 5 robot for select heart procedures, providing a new boost after the stock’s swings post-earnings last week.
Cardiac surgery is a major, high-risk field that’s been slow to adopt minimally invasive methods. Intuitive is betting that the da Vinci 5 clearance will expand the range of procedures performed with its systems, boosting ongoing sales of instruments and accessories.
This comes as investors weigh whether fresh indications and system placements can maintain growth, even as hospitals tighten budgets on costly equipment and competitors flood the market with more robotic platforms.
Intuitive announced that the FDA has cleared the da Vinci 5 system for certain thoracoscopic cardiac procedures. This includes mitral valve repair and internal mammary artery mobilization for revascularization, among other uses.
“Opening the chest to perform surgical procedures can involve significant pain, high risk of complications, and long recovery times,” said chief executive Dave Rosa in the statement announcing the clearance. GlobeNewswire
Only a handful of U.S. locations will team up with Intuitive through 2026 to launch da Vinci 5 cardiac programs, reported. These initiatives will cover procedures like tricuspid valve repair, mitral valve replacement, and left atrial appendage closure.
Valve and appendage procedures remain key to flagship offerings from heart-device giants like Abbott, Boston Scientific, and Edwards Lifesciences. This focus on cardiac care adds a wider competitive dimension beyond just surgical robots.
Intuitive informed investors last week that it anticipates da Vinci-assisted procedures to increase roughly 13% to 15% globally in 2026, down from 18% growth projected for 2025. The company also forecasted a gross margin between 67% and 68%, while noting an expected impact from tariffs.
The procedure-growth metric is crucial for the stock since every surgery drives demand for single-use tools and accessories. If growth slows in this area, it can weigh on expectations—even if system sales remain strong.
The downside scenario is clear: hospitals might be slow to embrace cardiac robotics, and scaling training pipelines could drag on. Plus, heart surgery demands high standards of evidence. Any hold-ups in launching initial U.S. programs, or quicker advances by robotic rivals, could undercut the immediate upside of the new clearance.
Investors are set to monitor the cardiac developments closely at the Society of Thoracic Surgeons annual meeting in New Orleans from Jan. 29 to Feb. 1. Intuitive plans to sponsor a robotic cardiac training session there.
